Arcapta contains the active ingredient indacaterol, a long-acting beta2-adrenergic agonist. When inhaled, indacaterol acts locally in the lung as a bronchodilator.
Arcapta is specifically approved for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.
Arcapta is supplied with inhalation powder capsules and an inhaler.
Submit your review
Adverse events associated with the use of Arcapta may include, but are not limited to, the following:
The recommended dose is the once-daily inhalation of the contents of one 75 mcg Arcapta capsule using the Neohaler inhaler. Arcapta should be administered once daily every day at the same time of the day by the orally inhaled route only.